Genetico Center (MOEX: GECO) held its XIII annual symposium, GENETICO.FBI, bringing together more than 100 specialists from various fields of medical genetics to discuss complex issues of genetic research interpretation.
The symposium program included 12 presentations. Speakers discussed the challenges of conducting and interpreting genetic studies, functional analysis, situations where the results of interpretation do not match initial expectations, as well as situations where errors in data interpretation can lead to serious consequences for patients and their families. Participants discussed how to improve the accuracy of laboratory research and how to properly process and analyze patient genetic data, considering ethical and responsibility issues.
During the presentations and subsequent discussion, topics included the specifics of genome sequencing data interpretation in apparently healthy individuals, pharmacogenetic testing for psychotropic drug selection, results of medical genetic testing in oncology, "invisible" mutations, the genetics of epilepsy, as well as general principles and individual challenges of functional analysis.
Genetico Center is one of the leaders in the field of medical genetics. The Company annually holds conferences dedicated to current and complex issues of genetics, bringing together specialists from various medical fields to exchange experience, discuss the latest research, clinical cases, innovative technologies, and modern methods of diagnosis and prevention of genetic diseases.
Opening the conference, Igor Zharkikh, Director of Genetico, noted: "Over 13 years of operation, Genetico's laboratories have analyzed more than 10,000 exomes, tested more than 80,000 embryos, and conducted more than 20,000 NIPTs. Genetico collaborates with 58 multidisciplinary clinics, 62 IVF centers, and more than 4,000 medical genetics specialists in 197 cities in the Russian Federation, Kazakhstan, Kyrgyzstan, Belarus, and Armenia. Genetico's services are becoming increasingly in demand, with annual revenue growth of 20%."
Genetico was one of the first to introduce advanced genetic tests PGT-M and NIPT into the widespread practice of Russian healthcare; these have been included in the compulsory health insurance (CHI) program since 2026.
Genetico began introducing PGT (genetic testing of embryos) into practical healthcare in 2012. Currently, every 7th IVF cycle in Russia is performed with PGT.
In 2017, Genetico localized NIPT technology to assess the risk of fetal chromosomal abnormalities during pregnancy using the mother's blood. In 2023, Genetico received permission to use its own NIPT — "Prenetix".
In 2025, Genetico received a patent for the Onconetix panel for genetic testing of tumors and selection of targeted therapy for oncological diseases. Onconetix is a panel developed at Genetico Center for detecting somatic mutations in tumors using next-generation sequencing (NGS).
Genetico Center (MOEX: GECO) is part of the Artgen Biotech Group (MOEX: ABIO), a resident of Skolkovo and MedTech Technopark. The Company operates in the field of medical genetics and genetic research, implementing innovative solutions for the diagnosis, prevention, and treatment of genetic, oncological, and other socially significant and orphan diseases into healthcare practice. Since 2023, the Company has been developing gene therapy drugs for the treatment of orphan diseases. Research is focused on the early stages of developing drug candidates for the treatment of eye diseases, hereditary cardiomyopathies, and neurodegenerative diseases.